BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35918798)

  • 21. Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer.
    Rendl G; Rettenbacher L; Schweighofer-Zwink G; Hehenwarter L; Pirich C
    Horm Metab Res; 2020 Mar; 52(3):158-167. PubMed ID: 32215887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
    Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer.
    Oh JR; Byun BH; Hong SP; Chong A; Kim J; Yoo SW; Kang SR; Kim DY; Song HC; Bom HS; Min JJ
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1459-68. PubMed ID: 21505897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Performance of
    Qiu ZL; Wei WJ; Shen CT; Song HJ; Zhang XY; Sun ZK; Luo QY
    Sci Rep; 2017 Jun; 7(1):2849. PubMed ID: 28588229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Liu J; Liu B; Yu Y; Chao F; Liu Y; Han X
    Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.
    Salvatore B; Klain M; Nicolai E; D'Amico D; De Matteis G; Raddi M; Fonti R; Pellegrino T; Storto G; Cuocolo A; Pace L
    Medicine (Baltimore); 2017 Oct; 96(42):e8344. PubMed ID: 29049252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [
    Albano D; Tulchinsky M; Dondi F; Mazzoletti A; Lombardi D; Bertagna F; Giubbini R
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):461-468. PubMed ID: 32794104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
    van Dijk D; Plukker JT; Phan HT; Muller Kobold AC; van der Horst-Schrivers AN; Jansen L; Sluiter WJ; Brouwers AH; Links TP
    Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
    Dong MJ; Liu ZF; Zhao K; Ruan LX; Wang GL; Yang SY; Sun F; Luo XG
    Nucl Med Commun; 2009 Aug; 30(8):639-50. PubMed ID: 19512954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
    Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.